Am J Manag Care. 2017 Nov;23(17 Suppl):S312-S316.
Stimulation of the cervical vagus nerve with implanted vagus nerve stimulation (iVNS) has been used clinically for more than 20 years to treat patients with epilepsy. More recently, a non-invasive cervical vagus nerve stimulation (nVNS), gammaCore, was developed, which has been purported to also stimulate the vagus nerve without the cost and morbidity associated with an iVNS system. gammaCore has been used to acutely treat various types of primary headaches, including migraine and cluster headaches (CH), and for the prevention of episodic, chronic, and menstrual migraines and CH. The gammaCore device was cleared by the FDA for the acute treatment of pain in episodic CH patients. In this review, we summarize the clinical work that has been published in the use of gammaCore for treating primary headache disorders, present an overview of studies demonstrating that nVNS does indeed stimulate similar vagus nerve fibers as the implantable VNS system, and then present several animal headache-related studies that address the mechanism of action of nVNS.
经植入式迷走神经刺激(iVNS)刺激颈部迷走神经在临床上已应用超过 20 年,用于治疗癫痫患者。最近,开发了一种非侵入性的颈部迷走神经刺激(nVNS)设备 gammaCore,据称它也可以刺激迷走神经,而不会产生 iVNS 系统相关的费用和发病率。gammaCore 已被用于急性治疗各种原发性头痛,包括偏头痛和丛集性头痛(CH),并用于预防发作性、慢性和月经性偏头痛和 CH。该 gammaCore 设备已获得 FDA 批准,可用于治疗发作性 CH 患者的急性疼痛。在这篇综述中,我们总结了已发表的关于 gammaCore 治疗原发性头痛障碍的临床研究,概述了证明 nVNS 确实可以刺激与植入式 VNS 系统相似的迷走神经纤维的研究,并介绍了几项与动物头痛相关的研究,这些研究探讨了 nVNS 的作用机制。